Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2024.01.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations.
Curr Res Transl Med
January 2025
Department of Diabetology and Endocrinology, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
Drug repurposing is a promising strategy for managing cardiovascular disease (CVD) in geriatric populations, offering efficient and cost-effective solutions. CVDs are prevalent across all age groups, with a significant increase in prevalence among geriatric populations. The middle-age period (40-65 years) is critical due to factors like obesity, sedentary lifestyle, and psychosocial stress.
View Article and Find Full Text PDFInvestigator-initiated, multi-center, single-arm, open-label study of the effectiveness of canakinumab in Japanese patients with Schnitzler syndrome.
Allergol Int
December 2024
Department of Dermatology, Hyogo Medical University Graduate School of Medicine, Nishinomiya, Japan.
Article Synopsis
- Schnitzler syndrome is an adult-onset autoinflammatory condition presenting with a rash, fever, and fatigue, but lacks an approved treatment, prompting this study on canakinumab.
- In this phase II trial, five patients received a single dose of canakinumab, with the goal of achieving a complete clinical response (CR) and tracking improvements in quality of life and inflammatory markers.
- The results indicated that 60% of patients achieved CR by Day 7, and all patients demonstrated improvements in inflammation and quality of life, suggesting canakinumab may be beneficial for those with Schnitzler syndrome.
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.
Nat Commun
November 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
In myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells' (HSPCs') aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis. To evaluate whether targeting the IL-1β signaling pathway can rescue ineffective erythropoiesis in patients with MDS, we designed a phase 2 non-randomized single-arm clinical trial (NCT04239157) to assess the safety profile and efficacy of the IL-1β inhibitor canakinumab in previously treated lower-risk MDS patients. We enrolled 25 patients with a median age of 74 years; 60% were male, 16% had lower-risk MDS, 84% had intermediate-1 risk MDS according to the International Prognostic Scoring System score, and 80% failed hypomethylating agent therapy.
View Article and Find Full Text PDFAdvances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions.
Int J Mol Sci
October 2024
Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, Taiwan.
Article Synopsis
- * The review discusses both established and new treatment options for gouty arthritis developed from 2019 to 2024, including pharmaceutical plant additives, anti-inflammatory agents like canakinumab, and lifestyle changes.
- * Promising new approaches aim to improve uric acid metabolism and reduce inflammation, but further research is needed to confirm their effectiveness and safety before they can be widely used in clinical practice.
Efficacy and safety of canakinumab in familial Mediterranean fever in Japan: a single-centre retrospective study.
Clin Exp Rheumatol
October 2024
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!